Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 5 , Pages 525-541 , October 2009

The pathophysiology of pituitary adenomas

  • Dorota Dworakowska, MD, PhD (Doctor)

      Affiliations

    • Centre for Endocrinology, Barts and the London School of Medicine, EC1M 6BQ, UK
    • Department of Endocrinology and Internal Medicine, Medical University of Gdańsk, 80-211, 7 Dębinki Str., Poland
    • ,
  • Ashley B. Grossman, MD, PhD (Professor of Neuroendocrinology)

      Affiliations

    • Centre for Endocrinology, Barts and the London School of Medicine, EC1M 6BQ, UK
    • Corresponding Author InformationCorresponding author. Centre for Endocrinology, St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK. Tel.: +44 20 76018343; Fax: +44 20 76018505.

References 

  1. Scheithauer BW, Gaffey TA, Lloyd RV, et al. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery. 2006;59:341–353[discussion -53]
  2. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101:613–619
  3. Daly AF, Burlacu MC, Livadariu E, et al. The epidemiology and management of pituitary incidentalomas. Hormone Research. 2007;68(Suppl. 5):195–198
  4. Lindholm J, Juul S, Jorgensen JO, et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. The Journal of Clinical Endocrinology and Metabolism. 2001;86:117–123
  5. Levy A. Molecular and trophic mechanisms of tumorigenesis. Endocrinology and Metabolism Clinics of North America. 2008;37:23–50vii
  6. Alexander JM, Biller BM, Bikkal H, et al. Clinically nonfunctioning pituitary tumors are monoclonal in origin. The Journal of Clinical Investigation. 1990;86:336–340
  7. Herman V, Fagin J, Gonsky R, et al. Clonal origin of pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism. 1990;71:1427–1433
  8. Melmed S. Pituitary neoplasia. Endocrinology and Metabolism Clinics of North America. 1994;23:81–92
  9. Gueorguiev M, Grossman AB. Pituitary gland and beta-catenin signaling: from ontogeny to oncogenesis. Pituitary. 2008;
  10. Levy A, Lightman S. Molecular defects in the pathogenesis of pituitary tumours. Frontiers in Neuroendocrinology. 2003;24:94–127
  11. Boikos SA, Stratakis CA. Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis. Human Molecular Genetics. 2007;16(Spec No 1):R80–R87
  12. Beckers A, Daly AF. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. European Journal of Endocrinology. 2007;157:371–382
  13. Karhu A, Aaltonen LA. Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update. Human Molecular Genetics. 2007;16(Spec No 1):R73–R79
  14. Horvath A, Stratakis CA. Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. Reviews in Endocrine & Metabolic Disorders. 2008;9:1–11
  15. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:15558–15563
  16. Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006;312:1228–1230
  17. Igreja S, Chahal HS, Akker SA, et al. Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and AIP (aryl hydrocarbon receptor-interacting protein) genes in MEN1 syndrome patients without any detectable MEN1 gene mutations. Clinical Endocrinology. 2008;
  18. Luccio-Camelo DC, Une KN, Ferreira RE, et al. A meiotic recombination in a new isolated familial somatotropinoma kindred. European Journal of Endocrinology. 2004;150:643–648
  19. Daly AF, Jaffrain-Rea ML, Ciccarelli A, et al. Clinical characterization of familial isolated pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism. 2006;91:3316–3323
  20. Spada A, Arosio M, Bochicchio D, et al. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. The Journal of Clinical Endocrinology and Metabolism. 1990;71:1421–1426
  21. Lania A, Mantovani G, Spada A. Genetics of pituitary tumors: focus on G-protein mutations. Experimental Biology and Medicine (Maywood, N.J.). 2003;228:1004–1017
  22. Burgess JR, Greenaway TM, Shepherd JJ. Expression of the MEN-1 gene in a large kindred with multiple endocrine neoplasia type 1. Journal of Internal Medicine. 1998;243:465–470
  23. Farrell WE, Simpson DJ, Bicknell J, et al. Sequence analysis and transcript expression of the MEN1 gene in sporadic pituitary tumours. British Journal of Cancer. 1999;80:44–50
  24. Satta MA, Korbonits M, Jacobs RA, et al. Expression of menin gene mRNA in pituitary tumours. European Journal of Endocrinology. 1999;140:358–361
  25. Poncin J, Stevenaert A, Beckers A. Somatic MEN1 gene mutation does not contribute significantly to sporadic pituitary tumorigenesis. European Journal of Endocrinology. 1999;140:573–576
  26. Dahia PL, Aguiar RC, Honegger J, et al. Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours. Oncogene. 1998;16:69–76
  27. Hai N, Aoki N, Shimatsu A, et al. Clinical features of multiple endocrine neoplasia type 1 (MEN1) phenocopy without germline MEN1 gene mutations: analysis of 20 Japanese sporadic cases with MEN1. Clinical Endocrinology. 2000;52:509–518
  28. Georgitsi M, Raitila A, Karhu A, et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. The Journal of Clinical Endocrinology and Metabolism. 2007;92:3321–3325
  29. Lloyd RV, Jin L, Qian X, et al. Aberrant p27kip1 expression in endocrine and other tumors. The American Journal of Pathology. 1997;150:401–407
  30. Lidhar K, Korbonits M, Jordan S, et al. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. The Journal of Clinical Endocrinology and Metabolism. 1999;84:3823–3830
  31. Milne TA, Hughes CM, Lloyd R, et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:749–754
  32. Drosten M, Hilken G, Bockmann M, et al. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. Journal of the National Cancer Institute. 2004;96:1231–1239
  33. Kolluri SK, Weiss C, Koff A, et al. p27(Kip1) induction and inhibition of proliferation by the intracellular Ah receptor in developing thymus and hepatoma cells. Genes & Development. 1999;13:1742–1753
  34. Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nature Genetics. 2000;26:89–92
  35. Bossis I, Voutetakis A, Matyakhina L, et al. A pleiomorphic GH pituitary adenoma from a Carney complex patient displays universal allelic loss at the protein kinase A regulatory subunit 1A (PRKARIA) locus. Journal of Medical Genetics. 2004;41:596–600
  36. Sandrini F, Kirschner LS, Bei T, et al. PRKAR1A, one of the Carney complex genes, and its locus (17q22–24) are rarely altered in pituitary tumours outside the Carney complex. Journal of Medical Genetics. 2002;39:e78
  37. Kaltsas GA, Kola B, Borboli N, et al. Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours. Clinical Endocrinology. 2002;57:443–448
  38. Georgitsi M, Raitila A, Karhu A, et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:4101–4105
  39. Daly AF, Vanbellinghen JF, Khoo SK, et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. The Journal of Clinical Endocrinology and Metabolism. 2007;92:1891–1896
  40. Gadelha MR, Une KN, Rohde K, et al. Isolated familial somatotropinomas: establishment of linkage to chromosome 11q13.1–11q13.3 and evidence for a potential second locus at chromosome 2p16–12. The Journal of Clinical Endocrinology and Metabolism. 2000;85:707–714
  41. Leontiou CA, Gueorguiev M, van der Spuy J, et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism. 2008;93:2390–2401
  42. Asa SL, Ezzat S. The pathogenesis of pituitary tumours. Nature Reviews. Cancer. 2002;2:836–849
  43. Karga HJ, Alexander JM, Hedley-Whyte ET, et al. Ras mutations in human pituitary tumors. The Journal of Clinical Endocrinology and Metabolism. 1992;74:914–919
  44. Herman V, Drazin NZ, Gonsky R, et al. Molecular screening of pituitary adenomas for gene mutations and rearrangements. The Journal of Clinical Endocrinology and Metabolism. 1993;77:50–55
  45. Boggild MD, Jenkinson S, Pistorello M, et al. Molecular genetic studies of sporadic pituitary tumors. The Journal of Clinical Endocrinology and Metabolism. 1994;78:387–392
  46. Cryns VL, Alexander JM, Klibanski A, et al. The retinoblastoma gene in human pituitary tumors. The Journal of Clinical Endocrinology and Metabolism. 1993;77:644–646
  47. Pei L, Melmed S, Scheithauer B, et al. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Research. 1995;55:1613–1616
  48. Tanizaki Y, Jin L, Scheithauer BW, et al. P53 gene mutations in pituitary carcinomas. Endocrine Pathology. 2007;18:217–222
  49. Zhang X, Horwitz GA, Heaney AP, et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism. 1999;84:761–767
  50. Zhang X, Sun H, Danila DC, et al. Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. The Journal of Clinical Endocrinology and Metabolism. 2002;87:1262–1267
  51. Zhang X, Zhou Y, Mehta KR, et al. A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. The Journal of Clinical Endocrinology and Metabolism. 2003;88:5119–5126
  52. Bahar A, Simpson DJ, Cutty SJ, et al. Isolation and characterization of a novel pituitary tumor apoptosis gene. Molecular Endocrinology. 2004;18:1827–1839
  53. Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Molecular Endocrinology. 1997;11:433–441
  54. Salehi F, Kovacs K, Scheithauer BW, et al. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocrine-related Cancer. 2008;15:721–743
  55. Bharadwaj R, Yu H. The spindle checkpoint, aneuploidy, and cancer. Oncogene. 2004;23:2016–2027
  56. Zou H, McGarry TJ, Bernal T, et al. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science. 1999;285:418–422
  57. Wang Z, Melmed S. Pituitary tumor transforming gene (PTTG) transforming and transactivation activity. The Journal of Biological Chemistry. 2000;275:7459–7461
  58. Chamaon K, Kirches E, Kanakis D, et al. Regulation of the pituitary tumor transforming gene by insulin-like-growth factor-I and insulin differs between malignant and non-neoplastic astrocytes. Biochemical and Biophysical Research Communications. 2005;331:86–92
  59. Tong Y, Tan Y, Zhou C, et al. Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition. Oncogene. 2007;26:5596–5605
  60. Chesnokova V, Zonis S, Rubinek T, et al. Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Research. 2007;67:10564–10572
  61. Chesnokova V, Kovacs K, Castro AV, et al. Pituitary hypoplasia in Pttg−/− mice is protective for Rb+/− pituitary tumorigenesis. Molecular Endocrinology. 2005;19:2371–2379
  62. Filippella M, Galland F, Kujas M, et al. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clinical Endocrinology. 2006;65:536–543
  63. McCabe CJ, Boelaert K, Tannahill LA, et al. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. The Journal of Clinical Endocrinology and Metabolism. 2002;87:4238–4244
  64. Minematsu T, Suzuki M, Sanno N, et al. PTTG overexpression is correlated with angiogenesis in human pituitary adenomas. Endocrine Pathology. 2006;17:143–153
  65. Saez C, Japon MA, Ramos-Morales F, et al. hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene. 1999;18:5473–5476
  66. Minematsu T, Egashira N, Kajiya H, et al. PTTG is a secretory protein in human pituitary adenomas and in mouse pituitary tumor cell lines. Endocrine Pathology. 2007;18:8–15
  67. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocrine-related Cancer. 2000;7:165–197
  68. Givol D, Yayon A. Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. The FASEB Journal. 1992;6:3362–3369
  69. Ezzat S, Smyth HS, Ramyar L, et al. Heterogenous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism. 1995;80:878–884
  70. Ezzat S, Zheng L, Zhu XF, et al. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. The Journal of Clinical Investigation. 2002;109:69–78
  71. Qian ZR, Sano T, Asa SL, et al. Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. The Journal of Clinical Endocrinology and Metabolism. 2004;89:1904–1911
  72. Musat M, Vax VV, Borboli N, et al. Cell cycle dysregulation in pituitary oncogenesis. Frontiers of Hormone Research. 2004;32:34–62
  73. Ogino A, Yoshino A, Katayama Y, et al. The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas. Journal of Neuropathology and Experimental Neurology. 2005;64:398–403
  74. Yoshino A, Katayama Y, Ogino A, et al. Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas. Journal of Neuro-oncology. 2007;83:153–162
  75. Bahar A, Bicknell JE, Simpson DJ, et al. Loss of expression of the growth inhibitory gene GADD45gamma, in human pituitary adenomas, is associated with CpG island methylation. Oncogene. 2004;23:936–944
  76. Simpson DJ, Clayton RN, Farrell WE. Preferential loss of Death Associated Protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion. Oncogene. 2002;21:1217–1224
  77. Farrell WE. A novel apoptosis gene identified in the pituitary gland. Neuroendocrinology. 2006;84:217–221
  78. Zhao J, Dahle D, Zhou Y, et al. Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. The Journal of Clinical Endocrinology and Metabolism. 2005;90:2179–2186
  79. Pagotto U, Arzberger T, Theodoropoulou M, et al. The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Research. 2000;60:6794–6799
  80. Korbonits M, Chahal HS, Kaltsas G, et al. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. The Journal of Clinical Endocrinology and Metabolism. 2002;87:2635–2643
  81. Jordan S, Lidhar K, Korbonits M, et al. Cyclin D and cyclin E expression in normal and adenomatous pituitary. European Journal of Endocrinology. 2000;143:R1–R6
  82. Ruebel KH, Leontovich AA, Jin L, et al. Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression. Endocrine. 2006;29:435–444
  83. Evans CO, Young AN, Brown MR, et al. Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. The Journal of Clinical Endocrinology and Metabolism. 2001;86:3097–3107
  84. Evans CO, Moreno CS, Zhan X, et al. Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses. Pituitary. 2008;11:231–245
  85. Moreno CS, Evans CO, Zhan X, et al. Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Research. 2005;65:10214–10222
  86. Elston MS, Gill AJ, Conaglen JV, et al. Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinology. 2008;149:1235–1242
  87. Morris DG, Musat M, Czirjak S, et al. Differential gene expression in pituitary adenomas by oligonucleotide array analysis. European Journal of Endocrinology. 2005;153:143–151
  88. Ribeiro-Oliveira A, Franchi G, Kola B, et al. Protein western array analysis in human pituitary tumours: insights and limitations. Endocrine-related Cancer. 2008;
  89. Zhan X, Evans CO, Oyesiku NM, et al. Proteomics and transcriptomics analyses of secretagogin down-regulation in human non-functional pituitary adenomas. Pituitary. 2003;6:189–202
  90. Beranova-Giorgianni S, Zhao Y, Desiderio DM, et al. Phosphoproteomic analysis of the human pituitary. Pituitary. 2006;9:109–120
  91. Morris DG, Kola B, Borboli N, et al. Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism. 2003;88:6080–6087
  92. Dahia PL, Honegger J, Reincke M, et al. Expression of glucocorticoid receptor gene isoforms in corticotropin-secreting tumors. The Journal of Clinical Endocrinology and Metabolism. 1997;82:1088–1093
  93. de Keyzer Y, Rene P, Beldjord C, et al. Overexpression of vasopressin (V3) and corticotrophin-releasing hormone receptor genes in corticotroph tumours. Clinical Endocrinology. 1998;49:475–482
  94. Dieterich KD, Gundelfinger ED, Ludecke DK, et al. Mutation and expression analysis of corticotropin-releasing factor 1 receptor in adrenocorticotropin-secreting pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism. 1998;83:3327–3331
  95. Dahia PL, Ahmed-Shuaib A, Jacobs RA, et al. Vasopressin receptor expression and mutation analysis in corticotropin-secreting tumors. The Journal of Clinical Endocrinology and Metabolism. 1996;81:1768–1771
  96. Korbonits M, Bujalska I, Shimojo M, et al. Expression of 11 beta-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: induction of the type 2 enzyme in corticotropinomas and other pituitary tumors. The Journal of Clinical Endocrinology and Metabolism. 2001;86:2728–2733
  97. Rabbitt EH, Ayuk J, Boelaert K, et al. Abnormal expression of 11 beta-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation. Oncogene. 2003;22:1663–1667
  98. Bilodeau S, Vallette-Kasic S, Gauthier Y, et al. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes & Development. 2006;20:2871–2886
  99. Drouin J, Bilodeau S, Vallette S. Of old and new diseases: genetics of pituitary ACTH excess (Cushing) and deficiency. Clinical Genetics. 2007;72:175–182
  100. Lee EJ, Kotlar TJ, Ciric I, et al. Absence of constitutively activating mutations in the GHRH receptor in GH-producing pituitary tumors. The Journal of Clinical Endocrinology and Metabolism. 2001;86:3989–3995
  101. Salvatori R, Thakker RV, Lopes MB, et al. Absence of mutations in the growth hormone (GH)-releasing hormone receptor gene in GH-secreting pituitary adenomas. Clinical Endocrinology. 2001;54:301–307
  102. Kola B, Korbonits M, Diaz-Cano S, et al. Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. Clinical Endocrinology. 2003;59:328–338
  103. Asa SL, Digiovanni R, Jiang J, et al. A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Research. 2007;67:7505–7511
  104. Greenman Y, Prager D, Melmed S. The IGF-I receptor sub-membrane domain is intact in GH-secreting pituitary tumours. Clinical Endocrinology. 1995;42:169–172
  105. Petersenn S, Heyens M, Ludecke DK, et al. Absence of somatostatin receptor type 2 A mutations and gip oncogene in pituitary somatotroph adenomas. Clinical Endocrinology. 2000;52:35–42
  106. Ballare E, Persani L, Lania AG, et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. The Journal of Clinical Endocrinology and Metabolism. 2001;86:3809–3814
  107. Giacomini D, Acuna M, Gerez J, et al. Pituitary action of cytokines: focus on BMP-4 and gp130 family. Neuroendocrinology. 2007;85:94–100
  108. Paez-Pereda M, Giacomini D, Refojo D, et al. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:1034–1039
  109. Korbonits M, Kojima M, Kangawa K, et al. Presence of ghrelin in normal and adenomatous human pituitary. Endocrine. 2001;14:101–104
  110. Nanzer AM, Khalaf S, Mozid AM, et al. Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway. European Journal of Endocrinology. 2004;151:233–240
  111. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. Journal of Clinical Oncology. 2005;23:5386–5403
  112. Rodriguez-Viciana P, Warne PH, Khwaja A, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell. 1997;89:457–467
  113. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature. 1997;385:544–548
  114. Volarevic S, Thomas G. Role of S6 phosphorylation and S6 kinase in cell growth. Progress in Nucleic Acid Research and Molecular Biology. 2001;65:101–127
  115. Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nature Cell Biology. 2002;4:648–657
  116. Sonenberg N, Gingras AC. The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Current Opinion in Cell Biology. 1998;10:268–275
  117. Rosenwald IB, Kaspar R, Rousseau D, et al. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. The Journal of Biological Chemistry. 1995;270:21176–21180
  118. Musat M, Korbonits M, Kola B, et al. Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocrine-related Cancer. 2005;12:423–433
  119. Dworakowska D, Grossman A. Are neuroendocrine tumours a feature of tuberous sclerosis?. Endocrine-related Cancer. 2009;16:45–58
  120. Haystead TA, Dent P, Wu J, et al. Ordered phosphorylation of p42mapk by MAP kinase kinase. FEBS Letters. 1992;306:17–22
  121. Terada Y, Nakashima O, Inoshita S, et al. Mitogen-activated protein kinase cascade and transcription factors: the opposite role of MKK3/6-p38K and MKK1-MAPK. Nephrology, Dialysis, Transplantation. 1999;14(Suppl. 1):45–47
  122. Terada Y, Inoshita S, Nakashima O, et al. Regulation of cyclin D1 expression and cell cycle progression by mitogen-activated protein kinase cascade. Kidney International. 1999;56:1258–1261
  123. Guan KL. The mitogen activated protein kinase signal transduction pathway: from the cell surface to the nucleus. Cellular Signalling. 1994;6:581–589
  124. Joneson T, Bar-Sagi D. Ras effectors and their role in mitogenesis and oncogenesis. Journal of Molecular Medicine. 1997;75:587–593
  125. Ewing I, Pedder-Smith S, Franchi G, et al. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clinical Endocrinology. 2007;66:348–352
  126. Dworakowska D, Teng M, Grozinsky-Glasberg S, et al. Extracellular signal-regulated kinase (ERK 1/2) overactivation in pituitary adenomas. The Endocrine Society's 90th Annual Meeting 2008, San Francisco, USA; 2008: [P3–514].
  127. Hibberts NA, Simpson DJ, Bicknell JE, et al. Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clinical Cancer Research. 1999;5:2133–2139
  128. McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Advances in Enzyme Regulation. 2006;46:249–279
  129. Vlotides G, Siegel E, Donangelo I, et al. Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Research. 2008;68:6377–6386
  130. Carbia-Nagashima A, Gerez J, Perez-Castro C, et al. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell. 2007;131:309–323
  131. Simpson DJ, Hibberts NA, McNicol AM, et al. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Research. 2000;60:1211–1216

PII: S1521-690X(09)00049-9

doi: 10.1016/j.beem.2009.05.004

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 5 , Pages 525-541 , October 2009

Article Tools

* Image Usage & Resolution